NeuroSense Therapeutics (NRSN) Corporate presentation summary

Corporate highlights and leadership

• Positive Phase 2b results for PrimeC in ALS, showing ~33% slower disease progression over 18 months (p=0.007).

• Patent protection for PrimeC extends to 2042.

• Expedited regulatory pathway with orphan drug designation and 505(b)(2) route.

• Experienced leadership and scientific advisory board with global neurology experts.

ALS market and unmet need

• ALS is a rapidly progressing, fatal disease with average survival of 2–5 years and limited treatment options.

• Over 200,000 ALS patients worldwide, with >30,000 in both North America and Europe.

• Current standard of care drugs offer only modest benefits.

• Projected ALS market opportunity exceeds $1B annually, with drug prices around $160,000/year.

PrimeC mechanism and clinical data

• PrimeC is a novel, extended-release combination of two approved drugs, targeting neuroinflammation, iron metabolism, and miRNA dysregulation.

• Demonstrated safety and tolerability in the PARADIGM Phase 2b trial, with most adverse events mild or moderate.

• Slowed ALS disease progression by 29.2% at 6 months and 32.8% at 18 months (p=0.007).

• Improved survival by 58% after 18 months and reduced complications.

• Biomarker data show modulation of key miRNAs and iron levels associated with ALS progression.